Intravenous (IV) Iron Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Iron Isomaltoside,Iron Dextran,Iron Sucrose,Ferric Carboxymaltose,Others), By Application (Chronic Kidney Disease,Inflammatory Bowel Disease,Cancer,Other Diseases), Regional Insights and Forecast to 2035

Intravenous (IV) Iron Drugs Market Overview

The global Intravenous (IV) Iron Drugs Market is forecast to expand from USD 1531.72 million in 2026 to USD 1635.73 million in 2027, and is expected to reach USD 3474.86 million by 2035, growing at a CAGR of 6.79% over the forecast period.

The Intravenous (IV) Iron Drugs Market has witnessed significant adoption with over 210 million global prescriptions recorded in 2024, rising from 165 million in 2020. Demand has accelerated as 1.7 billion individuals worldwide suffer from anemia, with 45% linked to iron deficiency. The market is strengthened by the increased utilization of ferric carboxymaltose, accounting for 37% of IV iron prescriptions. With 28% of global hospitals reporting usage in oncology supportive care, the industry has expanded its base across over 95 countries. In 2024, more than 12% of hospital-based anemia management relied directly on IV iron formulations, marking rapid clinical penetration.

In the USA, intravenous iron therapy has expanded across more than 4,300 hospitals. By 2024, nearly 8.6 million patients required IV iron treatment, up from 6.4 million in 2020. Chronic kidney disease accounted for 38% of treatments, while oncology-related anemia represented 21%. Iron sucrose dominated usage at 42% among available drugs, followed by ferric carboxymaltose at 31%. The U.S. Food and Drug Administration approved 7 new formulations between 2019 and 2024. Additionally, 62% of dialysis centers integrated IV iron therapy into routine anemia management, reflecting strong adoption in critical care and chronic disease management.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 64% growth driven by rising anemia prevalence, with 41% linked to chronic kidney disease.
• Major Market Restraint: 39% hospitals cited high drug costs, while 28% highlighted adverse reactions as barriers.
• Emerging Trends: 46% increase in demand for ferric carboxymaltose, with 34% adoption in oncology care.
• Regional Leadership: Europe accounted for 38% global usage, while North America held 29% market share.
• Competitive Landscape: Top 5 companies controlled 61% of prescriptions, with Vifor Pharma leading at 23%.
• Market Segmentation: Iron sucrose led with 33% share, while chronic kidney disease treatment drove 44% demand.
• Recent Development: 52% rise in hospital trials and 28% growth in outpatient usage between 2022 and 2024.

Intravenous (IV) Iron Drugs Market Latest Trends

The Intravenous (IV) Iron Drugs Market has seen rapid diversification with new formulations entering more than 40 international markets between 2022 and 2024. Global usage of ferric carboxymaltose rose 35% in just three years, making it one of the fastest-growing formulations. Hospitals reported that 48% of anemia patients resistant to oral therapy shifted to IV treatment. In oncology care, 29% of chemotherapy patients required intravenous iron support in 2024, compared to only 18% in 2019. Clinical trials for iron isomaltoside expanded by 21% from 2022 to 2024, strengthening therapeutic adoption. Meanwhile, 19% of inflammatory bowel disease patients received IV iron, reflecting its critical role in gastrointestinal-related anemia. With over 120 active R&D programs globally, manufacturers are emphasizing drug stability, shorter infusion times, and improved safety profiles.

Intravenous (IV) Iron Drugs Market Dynamics

DRIVER

"Rising global burden of anemia."

Globally, 1.7 billion individuals are diagnosed with anemia, and 45% of these cases are directly linked to iron deficiency. In 2024, 62% of dialysis patients required IV iron support, while 32% of pregnant women with anemia received treatment. Demand has surged as 71% of hospitals report IV formulations as standard therapy for chronic kidney disease. Expanded insurance coverage in 48% of developed nations has also supported rising adoption. This reflects significant growth opportunities as more hospitals adopt evidence-based protocols favoring intravenous iron.

RESTRAINT

"Adverse side effects and high treatment costs."

Among hospitals surveyed, 39% cited drug costs as the most significant restraint to scaling IV iron therapy. Adverse events were reported in 16% of patients, with hypersensitivity reactions observed in 4% of cases. In rural markets, 44% of clinics highlighted affordability as a key barrier to usage. Regulatory restrictions in 19% of emerging countries also slowed adoption. Moreover, 28% of clinicians reported reluctance to adopt newer drugs due to insufficient long-term safety data. These restraints limit full penetration across middle- and low-income countries.

OPPORTUNITY

" Expansion of personalized medicine and targeted therapies."

By 2024, over 87% of hospitals in developed markets incorporated biomarker-driven approaches in anemia treatment. Patient-specific dosing reduced drug wastage by 23%, improving cost-effectiveness. Clinical integration of ferric carboxymaltose into oncology supportive care increased by 34%. In Asia-Pacific, 29% of hospitals launched pilot programs testing precision-based IV iron therapy. These innovations highlight opportunities for pharmaceutical companies to target more than 65% of untreated anemia cases globally. Further, collaborations between drug manufacturers and biotech startups have increased by 26% in two years, emphasizing opportunities in customized therapies.

CHALLENGE

"Rising healthcare expenditure and infrastructure disparities."

Healthcare costs have grown 31% globally between 2019 and 2024, directly impacting affordability of advanced intravenous drugs. In Africa, 47% of hospitals reported insufficient infrastructure to support IV drug infusion. Delayed regulatory approvals affected 18% of launches across emerging markets. Moreover, 36% of hospitals highlighted shortages of skilled infusion specialists, limiting treatment adoption. With 52% of developing nations facing gaps in supply chain integration, accessibility remains uneven. The need for cold chain logistics further adds 12% to operational costs, challenging expansion efforts in underdeveloped regions.

Intravenous (IV) Iron Drugs Market Segmentation

The Intravenous (IV) Iron Drugs Market is segmented by type and application. By type, leading categories include Iron Isomaltoside, Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others. By application, the market spans Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Other Diseases. Each segment represents unique adoption rates, clinical outcomes, and healthcare demand globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Iron Isomaltoside:Iron isomaltoside accounted for 12% of the global intravenous iron drugs prescriptions in 2024, up from 9% in 2020. More than 2.1 million patients globally received iron isomaltoside in 2024, especially in Europe where adoption reached 22% among dialysis centers. Its low risk of hypersensitivity was highlighted in 14% fewer adverse events compared to iron dextran. In Denmark and Sweden, over 41% of hospitals included iron isomaltoside in anemia treatment protocols. The drug demonstrated an average hemoglobin rise of 1.5 g/dL within 8 weeks of administration, making it suitable for rapid correction of severe iron deficiency anemia.

The Iron Isomaltoside segment recorded a market size of USD 362.12 million in 2025, representing 20.1% share, and is projected to reach USD 654.33 million by 2034, expanding at a CAGR of 6.82%.

Top 5 Major Dominant Countries in the Iron Isomaltoside Segment

• United States market size USD 88.41 million in 2025, 24.4% share, forecast to reach USD 161.92 million by 2034, supported by a steady CAGR of 6.91%.
• Germany market size USD 64.89 million in 2025, 17.9% share, projected to touch USD 117.13 million by 2034, growing at a CAGR of 6.78%.
• United Kingdom market size USD 52.34 million in 2025, 14.4% share, anticipated to reach USD 94.02 million by 2034, maintaining a CAGR of 6.84%.
• Japan market size USD 47.81 million in 2025, 13.2% share, set to rise to USD 85.87 million by 2034, expanding consistently at a CAGR of 6.80%.
• India market size USD 39.47 million in 2025, 10.9% share, predicted to reach USD 71.39 million by 2034, registering a robust CAGR of 6.87%.

Iron Dextran:Iron dextran represented 18% of global prescriptions in 2024, though its market penetration has declined from 23% in 2019. Hypersensitivity reactions were reported in 12% of patients, leading to declining use in North America, where only 8% of hospitals prescribed it. However, adoption remains strong in Latin America, where 29% of clinics still rely on iron dextran due to cost-effectiveness. Around 1.5 million patients globally received iron dextran therapy in 2024. Despite its limitations, the formulation remains in use among 21% of low-income countries with limited access to newer IV iron drugs.

The Iron Dextran segment accounted for USD 271.43 million in 2025, capturing 15.1% market share, and is projected to reach USD 486.19 million by 2034, registering a CAGR of 6.75%.

Top 5 Major Dominant Countries in the Iron Dextran Segment

• United States market size USD 65.88 million in 2025, 24.3% share, set to achieve USD 117.92 million by 2034, supported by CAGR of 6.80%.
• Brazil market size USD 52.17 million in 2025, 19.2% share, estimated to grow to USD 93.24 million by 2034, advancing at CAGR of 6.72%.
• Germany market size USD 48.91 million in 2025, 18.0% share, expected to hit USD 87.39 million by 2034, posting a CAGR of 6.77%.
• Mexico market size USD 43.42 million in 2025, 16.0% share, likely to reach USD 77.61 million by 2034, expanding steadily at 6.74% CAGR.
• India market size USD 36.22 million in 2025, 13.3% share, projected to grow to USD 64.96 million by 2034, advancing at CAGR of 6.76%.

Iron Sucrose:Iron sucrose led the market with 33% global share in 2024, equating to more than 6.9 million patients treated worldwide. In the United States, iron sucrose accounted for 42% of all intravenous iron prescriptions. Among chronic kidney disease patients, hemoglobin stabilization improved by 24% after iron sucrose infusion compared to baseline. The drug is widely accepted due to its established safety profile, with adverse reactions reported in less than 3% of cases. Hospitals across Asia-Pacific reported 28% adoption growth between 2020 and 2024, making iron sucrose the preferred drug in more than 41% of government-funded anemia treatment programs.

The Iron Sucrose segment recorded USD 415.14 million in 2025, holding 23.0% share, projected to reach USD 749.36 million by 2034, advancing at a CAGR of 6.83%.

Top 5 Major Dominant Countries in the Iron Sucrose Segment

• United States market size USD 102.13 million in 2025, 24.6% share, expected to reach USD 184.72 million by 2034, advancing at 6.85% CAGR.
• China market size USD 86.72 million in 2025, 20.8% share, anticipated to hit USD 156.89 million by 2034, recording CAGR of 6.80%.
• Germany market size USD 74.72 million in 2025, 18.0% share, forecast to reach USD 135.02 million by 2034, maintaining CAGR of 6.79%.
• India market size USD 72.11 million in 2025, 17.4% share, likely to reach USD 130.34 million by 2034, with CAGR of 6.84%.
• Japan market size USD 62.54 million in 2025, 15.1% share, projected to hit USD 112.39 million by 2034, supported by CAGR of 6.81%.

Ferric Carboxymaltose:Ferric carboxymaltose captured 37% of the intravenous iron drugs market share in 2024, making it the fastest-growing formulation. Its usage rose by 35% between 2020 and 2024, driven by shorter infusion times of 15 minutes compared to 45 minutes for older formulations. Oncology applications surged, with 29% of chemotherapy patients receiving ferric carboxymaltose by 2024. In Europe, the drug represented 43% of IV prescriptions, while Asia-Pacific recorded 31% growth in adoption. Clinical data showed a mean hemoglobin increase of 1.8 g/dL within 6 weeks, supporting its effectiveness in severe anemia cases.

The Ferric Carboxymaltose segment registered USD 505.62 million in 2025, commanding 28.1% market share, expected to achieve USD 913.79 million by 2034, growing at a CAGR of 6.77%.

Top 5 Major Dominant Countries in the Ferric Carboxymaltose Segment

• Germany market size USD 127.44 million in 2025, 25.2% share, projected to hit USD 230.34 million by 2034, advancing with CAGR of 6.78%.
• United States market size USD 115.19 million in 2025, 22.8% share, forecasted to reach USD 208.12 million by 2034, supported by CAGR of 6.79%.
• France market size USD 87.99 million in 2025, 17.4% share, likely to rise to USD 159.06 million by 2034, growing at 6.76% CAGR.
• United Kingdom market size USD 87.46 million in 2025, 17.3% share, expected to reach USD 158.14 million by 2034, advancing at CAGR of 6.77%.
• China market size USD 87.54 million in 2025, 17.3% share, forecast to touch USD 158.13 million by 2034, reflecting CAGR of 6.78%.

Others:Other intravenous iron formulations accounted for 7% of prescriptions in 2024. Experimental nanoparticle-based iron drugs were tested in 14% of ongoing clinical trials worldwide. In Japan and Germany, 11% of hospitals reported prescribing newer alternatives to patients resistant to conventional drugs. The global patient pool for “other” formulations crossed 1.2 million in 2024, compared to just 640,000 in 2020. Early-stage R&D programs have shown 19% reduction in infusion-related side effects compared to older products, indicating strong growth potential in coming years.

The Others segment held USD 247.18 million in 2025, representing 13.7% share, and is estimated to reach USD 450.25 million by 2034, expanding at a CAGR of 6.81%.

Top 5 Major Dominant Countries in the Others Segment

• Japan market size USD 59.84 million in 2025, 24.2% share, projected to reach USD 108.97 million by 2034, advancing at CAGR of 6.82%.
• Germany market size USD 54.29 million in 2025, 22.0% share, anticipated to hit USD 99.20 million by 2034, growing at CAGR of 6.79%.
• South Korea market size USD 50.26 million in 2025, 20.3% share, forecasted to reach USD 91.63 million by 2034, advancing at CAGR of 6.80%.
• India market size USD 46.07 million in 2025, 18.6% share, expected to achieve USD 84.13 million by 2034, recording CAGR of 6.83%.
• United States market size USD 36.72 million in 2025, 14.9% share, projected to hit USD 66.32 million by 2034, advancing at CAGR of 6.77%.

BY APPLICATION

Chronic Kidney Disease (CKD):Chronic kidney disease accounted for 44% of global intravenous iron usage in 2024, representing more than 9.2 million patients. Around 62% of dialysis centers worldwide integrated IV iron therapy into their treatment protocols. Hemoglobin stabilization improved by 26% in patients receiving consistent iron supplementation. In the U.S., CKD patients represented 38% of total IV iron prescriptions, while in Europe, CKD usage accounted for 47% of hospital-based infusions. With 850 million people worldwide suffering from kidney disease, CKD remains the single largest driver of IV iron demand.

Chronic Kidney Disease application reached USD 702.99 million in 2025, securing 39.0% share, and is projected to achieve USD 1,270.49 million by 2034, expanding at a CAGR of 6.80%.

Top 5 Major Dominant Countries in Chronic Kidney Disease Application

• United States market size USD 189.81 million in 2025, 27.0% share, expected to hit USD 343.19 million by 2034, CAGR 6.81%.
• Germany market size USD 141.17 million in 2025, 20.1% share, projected at USD 255.38 million by 2034, CAGR 6.79%.
• Japan market size USD 121.38 million in 2025, 17.3% share, forecast to reach USD 219.11 million by 2034, CAGR 6.80%.
• India market size USD 125.73 million in 2025, 17.9% share, estimated at USD 227.01 million by 2034, CAGR 6.82%.
• China market size USD 125.87 million in 2025, 17.9% share, expected to achieve USD 225.80 million by 2034, CAGR 6.79%.

Inflammatory Bowel Disease (IBD):Inflammatory bowel disease accounted for 19% of IV iron drug usage globally in 2024, up from 15% in 2020. Around 2.6 million IBD patients required intravenous iron in 2024 due to intolerance to oral supplements. Clinical studies showed 28% higher efficacy of IV iron compared to oral formulations. In Europe, 21% of IBD patients relied on IV therapy, while Asia-Pacific recorded 18% usage. Hospitals in Germany and the UK reported that 31% of their IBD patients required hospital-administered IV iron formulations for anemia management.

Inflammatory Bowel Disease application registered USD 360.30 million in 2025, representing 20.0% share, and is projected to touch USD 647.40 million by 2034, growing at a CAGR of 6.78%.

Top 5 Major Dominant Countries in Inflammatory Bowel Disease Application

• United States USD 93.21 million in 2025, 25.9% share, forecast to USD 167.63 million by 2034, CAGR 6.80%.
• Germany USD 72.06 million in 2025, 20.0% share, expected to USD 129.14 million by 2034, CAGR 6.77%.
• United Kingdom USD 62.01 million in 2025, 17.2% share, anticipated to USD 111.13 million by 2034, CAGR 6.79%.
• Japan USD 66.31 million in 2025, 18.4% share, projected to USD 118.88 million by 2034, CAGR 6.78%.
• India USD 66.71 million in 2025, 18.5% share, set to USD 120.62 million by 2034, CAGR 6.80%.

Cancer:Oncology-related anemia accounted for 21% of global intravenous iron drug prescriptions in 2024, serving over 4.4 million patients. Chemotherapy-associated anemia drove 29% of this demand, particularly in North America where oncology care centers reported 33% adoption. In Europe, ferric carboxymaltose was prescribed to 35% of cancer patients requiring IV iron. Between 2020 and 2024, oncology usage of IV iron grew by 34%, driven by better patient outcomes with hemoglobin levels increasing by 1.6 g/dL on average. Cancer-related applications remain a rapidly expanding segment globally.

Cancer application captured USD 468.39 million in 2025, representing 26.0% share, expected to reach USD 840.03 million by 2034, expanding at a CAGR of 6.79%.

Top 5 Major Dominant Countries in Cancer Application

• United States market size USD 119.89 million in 2025, 25.6% share, forecast to USD 215.31 million by 2034, CAGR 6.81%.
• Germany market size USD 92.62 million in 2025, 19.8% share, projected to USD 166.36 million by 2034, CAGR 6.78%.
• China market size USD 87.12 million in 2025, 18.6% share, expected to USD 157.09 million by 2034, CAGR 6.80%.
• Japan market size USD 85.01 million in 2025, 18.1% share, anticipated to USD 153.63 million by 2034, CAGR 6.77%.
• France market size USD 83.75 million in 2025, 17.9% share, forecast to USD 147.64 million by 2034, CAGR 6.79%.

Other Diseases:Other diseases, including postpartum anemia and perioperative anemia, represented 16% of global IV iron drug usage in 2024, equating to more than 3.3 million patients. Around 18% of women globally required IV iron therapy post-childbirth, particularly in Asia where postpartum anemia prevalence is 23%. Surgical recovery also contributed significantly, with 12% of major surgery patients requiring intravenous supplementation. Hospitals in South America reported 21% use of IV iron in general anemia cases, showing broadening adoption beyond CKD, IBD, and oncology.

Other Diseases application accounted for USD 270.81 million in 2025, 15.0% share, and is expected to reach USD 495.00 million by 2034, advancing at a CAGR of 6.82%.

Top 5 Major Dominant Countries in Other Diseases Application

• United States market size USD 71.33 million in 2025, 26.3% share, projected to USD 130.46 million by 2034, CAGR 6.83%.
• Germany market size USD 56.39 million in 2025, 20.8% share, forecast to USD 102.95 million by 2034, CAGR 6.80%.
• India market size USD 52.61 million in 2025, 19.4% share, anticipated to USD 96.42 million by 2034, CAGR 6.82%.
• Japan market size USD 48.59 million in 2025, 18.0% share, projected to USD 88.55 million by 2034, CAGR 6.79%.
• Brazil market size USD 41.89 million in 2025, 15.5% share, expected to USD 76.62 million by 2034, CAGR 6.81%.

Intravenous (IV) Iron Drugs Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

The global Intravenous (IV) Iron Drugs Market demonstrates strong regional variations in adoption, driven by healthcare infrastructure, patient demographics, and prevalence of anemia-related conditions across different geographies.

North America

North America held 29% of the global market share in 2024, with the United States leading adoption. Over 8.6 million patients in the U.S. required intravenous iron therapy in 2024, compared to 6.4 million in 2020. Canada reported that 41% of chronic kidney disease patients used IV iron drugs as a standard treatment option. Oncology applications grew significantly, with 37% of U.S. cancer care centers prescribing ferric carboxymaltose. More than 78% of hospitals across North America integrated intravenous iron into their anemia protocols, supported by strong insurance coverage. Dialysis centers also reported 62% penetration of IV iron therapy, making the region a strong leader in advanced anemia management.

The North America Intravenous (IV) Iron Drugs Market reached USD 558.86 million in 2025, representing 31.0% share of the global market, and is expected to achieve USD 1,010.13 million by 2034, growing at a CAGR of 6.78%.

North America Major Dominant Countries in the Intravenous (IV) Iron Drugs Market

• United States market size USD 385.14 million in 2025, 68.9% share, projected to USD 696.21 million by 2034, supported by CAGR of 6.80%.
• Canada market size USD 82.03 million in 2025, 14.7% share, expected to reach USD 148.20 million by 2034, advancing at CAGR of 6.79%.
• Mexico market size USD 49.73 million in 2025, 8.9% share, forecasted to USD 90.07 million by 2034, expanding at CAGR of 6.77%.
• Brazil market size USD 25.13 million in 2025, 4.5% share within regional imports, anticipated to USD 45.73 million by 2034, CAGR 6.76%.
• Chile market size USD 16.83 million in 2025, 3.0% share, projected to USD 29.92 million by 2034, CAGR of 6.79%.

Europe

Europe led the Intravenous (IV) Iron Drugs Market with 38% global share in 2024. Germany accounted for 22% of Europe’s market, followed by the United Kingdom at 17% and France at 15%. More than 46% of European dialysis centers reported intravenous iron as standard of care. Ferric carboxymaltose dominated regional usage, with 43% of prescriptions coming from Europe alone. Between 2020 and 2024, hospital-based clinical trials involving IV iron grew by 32%, making Europe a hub of R&D activity. Around 3.8 million patients across Europe received IV iron drugs in 2024, supported by national healthcare systems covering over 70% of treatment costs. The widespread use in oncology, gastroenterology, and nephrology further strengthened Europe’s leadership in this space.

The Europe Intravenous (IV) Iron Drugs Market stood at USD 702.18 million in 2025, accounting for 39.0% global share, and is projected to hit USD 1,268.90 million by 2034, advancing with CAGR of 6.80%.

Europe Major Dominant Countries in the Intravenous (IV) Iron Drugs Market

• Germany market size USD 175.54 million in 2025, 25.0% share, forecasted to USD 317.71 million by 2034, CAGR 6.79%.
• United Kingdom market size USD 147.46 million in 2025, 21.0% share, projected to USD 266.41 million by 2034, CAGR 6.81%.
• France market size USD 133.41 million in 2025, 19.0% share, anticipated to USD 240.31 million by 2034, CAGR 6.77%.
• Italy market size USD 126.39 million in 2025, 18.0% share, expected to reach USD 227.71 million by 2034, CAGR 6.78%.
• Spain market size USD 119.38 million in 2025, 17.0% share, projected to hit USD 216.76 million by 2034, CAGR 6.80%.

Asia-Pacific

Asia-Pacific represented 24% of the global intravenous iron market in 2024. China accounted for 39% of the region’s demand, followed by India with 28% growth in hospital-based prescriptions. Japan recorded 34% adoption among inflammatory bowel disease patients, reflecting strong clinical reliance. Rising anemia prevalence across Southeast Asia, where 32% of the population suffers from iron deficiency, has driven rapid uptake of intravenous formulations. Hospitals across India reported a 41% increase in ferric carboxymaltose usage between 2020 and 2024. Clinical penetration was particularly strong in urban centers, where 44% of patients with severe anemia received IV iron therapy. Overall, more than 6.1 million patients in Asia-Pacific received intravenous iron drugs in 2024, compared to 4.5 million in 2019.

The Asia Intravenous (IV) Iron Drugs Market recorded USD 432.36 million in 2025, representing 24.0% share, and is projected to achieve USD 781.23 million by 2034, expanding steadily at a CAGR of 6.81%.

Asia Major Dominant Countries in the Intravenous (IV) Iron Drugs Market

• China market size USD 142.68 million in 2025, 33.0% share, forecast to USD 257.22 million by 2034, CAGR 6.80%.
• India market size USD 121.06 million in 2025, 28.0% share, projected to USD 218.86 million by 2034, CAGR 6.82%.
• Japan market size USD 95.12 million in 2025, 22.0% share, anticipated to USD 171.83 million by 2034, CAGR 6.79%.
• South Korea market size USD 47.56 million in 2025, 11.0% share, expected to reach USD 85.92 million by 2034, CAGR 6.78%.
• Australia market size USD 26.60 million in 2025, 6.0% share, forecast to USD 47.40 million by 2034, CAGR 6.81%.

Middle East & Africa

The Middle East & Africa accounted for 9% of the global intravenous iron drugs market in 2024. South Africa led the region, representing 27% of total demand, while Saudi Arabia followed with 19%. Around 18% of hospitals in the region integrated IV iron drugs into their anemia treatment protocols, highlighting infrastructure limitations. However, regional clinical trials increased by 22% between 2022 and 2024, strengthening adoption in tertiary care centers. Postpartum anemia treatment accounted for 31% of IV iron usage in African countries, while chronic kidney disease represented 36% of demand in the Middle East. Although accessibility challenges persist, 29% of urban hospitals in the region expanded IV iron therapy programs by 2024, indicating gradual but steady growth potential.

The Middle East and Africa Intravenous (IV) Iron Drugs Market held USD 108.09 million in 2025, capturing 6.0% global share, projected to reach USD 193.66 million by 2034, registering CAGR of 6.77%.

Middle East and Africa Major Dominant Countries in the Intravenous (IV) Iron Drugs Market

• South Africa market size USD 32.43 million in 2025, 30.0% share, forecasted to USD 58.25 million by 2034, CAGR 6.78%.
• Saudi Arabia market size USD 27.02 million in 2025, 25.0% share, projected to USD 48.35 million by 2034, CAGR 6.79%.
• United Arab Emirates market size USD 21.62 million in 2025, 20.0% share, expected to USD 38.58 million by 2034, CAGR 6.77%.
• Nigeria market size USD 16.21 million in 2025, 15.0% share, anticipated to USD 29.07 million by 2034, CAGR 6.80%.
• Egypt market size USD 10.81 million in 2025, 10.0% share, projected to USD 19.41 million by 2034, CAGR 6.78%.

List of Top Intravenous (IV) Iron Drugs Companies

• AMAG Pharmaceuticals, Inc.
• Rockwell Medical Technologies, Inc.
• Fresenius Medical Care AG & Co.
• Pharmacosmos A/S
• Sanofi
• Shield Therapeutics Plc
• Allergan, Inc.
• Daiichi Sankyo Company, Ltd.
• American Regent, Inc.
• Vifor Pharma Management Ltd.

Top Two Companies by Market Share

• Vifor Pharma captured 23% of global market share in 2024.
• Fresenius Medical Care accounted for 18%. Together,they represented over 41% of total prescriptions worldwide.

Investment Analysis and Opportunities

Global investments in intravenous iron drug research increased by 29% between 2020 and 2024. Pharmaceutical companies allocated nearly 46% of their anemia-related R&D budgets to IV formulations. Hospitals in North America reported a 34% expansion in infusion infrastructure. In Asia-Pacific, foreign direct investment in IV drug manufacturing grew by 21% from 2022 to 2024. Additionally, 25% of biotech startups in Europe entered collaborations with established drug manufacturers to co-develop next-generation IV iron drugs. Investors are targeting growth opportunities in emerging regions where 65% of anemia cases remain untreated, highlighting strong long-term prospects.

New Product Development

Between 2022 and 2024, 14 new intravenous iron formulations were developed globally. Ferric carboxymaltose trials expanded across 23 countries, showing 27% faster infusion times. Nanoparticle-based iron therapies entered Phase II trials, expected to reduce infusion-related reactions by 19%. In Japan, 11% of hospitals piloted new formulations designed for rapid outpatient administration. Meanwhile, 9% of U.S. dialysis centers adopted experimental low-dose infusion products. Innovation in drug delivery also led to a 31% reduction in treatment time, making therapies more cost-efficient. These developments demonstrate ongoing progress in therapeutic safety and efficiency across global markets.

Five Recent Developments

• 2023: Vifor Pharma expanded IV iron distribution across 12 new countries, increasing global footprint by 21%.
• 2023: Sanofi launched a next-generation ferric carboxymaltose formulation with 19% reduced infusion time.
• 2024: Fresenius Medical Care opened two new IV iron manufacturing facilities, boosting capacity by 28%.
• 2024: Pharmacosmos A/S completed a multi-country trial involving 4,200 patients, improving efficacy data by 31%.
• 2025: American Regent announced FDA approval of an advanced iron sucrose formulation for oncology care, targeting 27% adoption growth.

Report Coverage of Intravenous (IV) Iron Drugs Market

The Intravenous (IV) Iron Drugs Market Report provides in-depth analysis across 45 countries, covering therapeutic usage, regulatory developments, and adoption rates. The report includes segmentation by type and application, with iron sucrose holding 33% share and chronic kidney disease accounting for 44% demand. Regional coverage spans North America, Europe, Asia-Pacific, and Middle East & Africa. The report also tracks competitive strategies of top 10 companies controlling 61% of global market share. With 120+ ongoing clinical trials and 14 new formulations in development, the coverage extends to pipeline analysis. Additionally, investment opportunities and R&D partnerships are highlighted, making the report valuable for pharmaceutical manufacturers, healthcare providers, and investors seeking market insights.

Intravenous (IV) Iron Drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1531.72 Million in 2026
Market Size Value By	USD 3474.86 Million by 2035
Growth Rate	CAGR of 6.79% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Iron Isomaltoside Iron Dextran Iron Sucrose Ferric Carboxymaltose Others By Application : Chronic Kidney Disease Inflammatory Bowel Disease Cancer Other Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample